Tirzepatide (Zepbound) - A New FDA-approved Treatment for Weight Loss. Complete Drug Review. 

This video is a complete drug review of tirzepatide (Zepbound), the latest FDA-approved injectable weight loss medication for obese and overweight individuals. Tirzepatide is given as a once a week injection under the skin. It is the first “dual-agonist” weight loss drug because it mimics two incretin hormones in the body, GLP-1 and GIP. In a large clinical study involving non-diabetic obese patients, tirzepatide at a dose of 15 mg weekly demonstrated an 18% reduction in weight compared to placebo after 72 weeks of treatment. The dose must be slowly titrated upward to reach the target dose to reduce the incidence of gastrointestinal adverse effects. The cost of Zepbound is $1060 for a one month’s supply. Patients who are commercially insured may be eligible for a discounted price.